Trial Profile
Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: CR-SEQUENCE
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms CR-SEQUENCE
- 27 Dec 2023 Planned End Date changed from 15 Jun 2025 to 28 Jun 2025.
- 27 Dec 2023 Planned primary completion date changed from 15 Jun 2024 to 28 Jun 2025.
- 07 Aug 2023 Planned primary completion date changed from 15 Jun 2023 to 15 Jun 2024.